Skip to content

Contact +44 (0) 20 7060 7474 email us

Production / Manufacturing

Key Players in Pharmaceutical Contract Manufacturing

Market developments, outsourcing hotspots and growth strategies

Publication Date March 2009
Publisher Business Insights
Product Type Report
Pages 144
ISBN Number not applicable
Product Code RBI00192

Price

£2,025.00
approximately: $3,066 | €2,260

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

This report aims to identify the hotspots and profile the leading players in the global pharmaceutical contract manufacturing market. It analyses company developments in the light of industry size, industry structure, service offerings, new technologies, major strategies and competitive situation, to discern trends of the industry as well its major players. It also analyses the current market scenario to identify the hotspots for contract manufacturing.

Contents

  • Key Players in Pharmaceutical Contract Manufacturing
  • Executive summary
  • Market development
  • Catalent
  • Lonza
  • Boehringer Ingelheim (BI)
  • DSM
  • Evonik
  • Patheon
  • Piramal
  • Jubilant
  • Aenova
  • Fareva
  • Chapter 1 Introduction
    • What is this report about?
    • Methodology
  • Chapter 2 Market development
    • Summary
    • Overview
    • Market size and growth
    • Positioning and performance of leading players
    • Drivers of manufacturing outsourcing
    • Key trends in the market
    • Increasing offshore outsourcing by Big Pharma
    • Expansion of biopharmaceutical contract manufacturing
    • Industry consolidation
    • Contract manufacturing hotspots - India and China
    • India
    • Contract manufacturing in India
    • Key CMOs in India
    • China
    • Contract Manufacturing in China
    • Key CMOs in China
    • Comparison of India and China on key parameters
    • Availability of skilled labor
    • Cost
    • Manufacturing infrastructure
    • Global capabilities
    • Service portfolio
    • Concerns about offshoring
  • Chapter 3 Catalent
    • Summary
    • Company overview
    • Group structure
    • Oral Technologies
    • Sterile Technologies
    • Packaging Services
    • Recent financial performance
    • Performance by business segments
    • Oral Technologies
    • Sterile Technologies
    • Packaging Services
    • Performance by geographies
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
  • Chapter 4 Lonza
    • Summary
    • Company overview
    • Group structure
    • Life Science Ingredients
    • Exclusive Synthesis & Biopharmaceuticals
    • Bioscience
    • Recent financial performance
    • Performance by business segments
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
    • Capacity expansion
    • Strategic partnerships and acquisitions
    • High value products
  • Chapter 5 Boehringer Ingelheim (BI)
    • Summary
    • Company overview
    • Group structure
    • Biopharmaceuticals
    • Pharmaceuticals Production
    • Pharma Chemicals
    • Recent financial performance
    • Performance by business segments
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
    • Capacity expansion
    • Strategic partnerships
  • Chapter 6 Royal DSM (DSM)
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
  • Chapter 7 Evonik (Degussa)
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
    • Restructuring of operations
    • Geographic restructuring
    • Capacity expansion
    • Geographic expansion
  • Chapter 8 Patheon
    • Summary
    • Company overview
    • Group structure
    • Commercial Manufacturing
    • Pharmaceutical Development Services (PDS)
    • Recent financial performance
    • Performance by business segments
    • Performance by geographies
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
    • Focus on prescription drugs business
    • Improve profitability and capacity utilization
    • Diversify customer base
  • Chapter 9 Piramal Healthcare (Piramal)
    • Summary
    • Company overview
    • Group structure
    • PDS (Pharmaceutical Development Services)
    • PMS (Pharmaceutical Manufacturing Services)
    • MMBB (Manufacturing Molecules/ Building Blocks)
    • Others
    • Recent financial performance
    • Performance by business segments
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
  • Chapter 10 Jubilant Organosys (Jubilant)
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Performance by product segments
    • Performance by geographies
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
  • Chapter 11 Aenova
    • Summary
    • Company overview
    • Group structure
    • Swiss Caps
    • Dragenopharm
    • Recent financial performance
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
  • Chapter 12 Fareva
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Manufacturing and R&D
    • Acquisitions and divestments
    • Growth strategies
  • Chapter 13 11 to 20 Companies
    • Nipro
    • Company overview
    • Recent financial performance
    • Siegfried
    • Company description
    • Recent financial performance
    • Haupt
    • Company description
    • Recent financial performance
    • Divi's Laboratories (Divi's)
    • Company description
    • Recent financial performance
    • Cambrex
    • Company description
    • Recent financial performance
    • Recipharm
    • Company description
    • Recent financial performance
    • Archimica
    • Company description
    • Vetter
    • Company description
    • Famar
    • Company description
    • NextPharma
    • Company description
    • Other contract manufacturers
    • Index
  • List of Figures
    • Figure 2.1: Global pharmaceutical contract manufacturing market size, 2007-2011
    • Figure 2.2: Positioning of leading players (2007)*
    • Figure 2.3: Labor cost in select countries
    • Figure 2.4: No. of FDA approved plants outside the US, 2007
    • Figure 3.5: Catalent's financial performance ($m), 2004-2008*
    • Figure 3.6: Catalent's revenue break-up by geography (%), 2008
    • Figure 4.7: Lonza's contract manufacturing financial performance ($m), 2005-2007*
    • Figure 5.8: BI Industrial Customers' financial performance ($m), 2005-2007*
    • Figure 6.9: DSM DPP's financial performance ($m), 2005-2007*
    • Figure 7.10: Evonik's Health & Nutrition financial performance ($m), 2006-2007*
    • Figure 8.11: Patheon's financial performance ($m), 2006-2008*
    • Figure 8.12: Patheon's Commercial Manufacturing revenue break-up by geography (%), 2008*
    • Figure 9.13: Piramal Pharma Solutions' financial performance ($m), 2006-2007*
    • Figure 10.14: Jubilant's CRAMS financial performance ($m), 2003-2007*
    • Figure 10.15: Jubilant's revenue break-up by geography (%), 2007*
    • Figure 12.16: Fareva Pharmaceuticals' financial performance ($m), 2006-2008*
    • Table 2.1: Leading pharmaceutical contract manufacturing companies, 2007
    • Table 2.2: Select manufacturing outsourcing initiatives planned by the Big Pharma
    • Table 2.3: Leading CMOs in India
    • Table 2.4: Select foreign acquisitions by Indian players
    • Table 2.5: Manufacturing cost comparison
    • Table 3.6: Catalent's snapshot
    • Table 3.7: Catalent's financial performance ($m), 2004-2008
    • Table 3.8: Catalent's business segments performance ($m), 2006-2008
    • Table 3.9: Catalent's performance by geography ($m), 2006-2008
    • Table 4.10: Lonza's snapshot
    • Table 4.11: Lonza's contract manufacturing financial performance ($m), 2005-2007
    • Table 4.12: Lonza's contract manufacturing business segments performance ($m), 2005-2007
    • Table 5.13: BI's snapshot
    • Table 5.14: BI Industrial Customers' financial performance ($m), 2005-2007
    • Table 5.15: BI Industrial Customers' business segments performance ($m), 2005-2007
    • Table 6.16: DSM's snapshot
    • Table 6.17: DSM DPP's financial performance ($m), 2005-2007
    • Table 7.18: Evonik's snapshot
    • Table 7.19: Evonik's Health & Nutrition financial performance ($m), 2006-2007
    • Table 8.20: Patheon's snapshot
    • Table 8.21: Patheon's financial performance ($m), 2006-2008
    • Table 8.22: Patheon's business segments performance ($m), 2008
    • Table 8.23: Patheon's Commercial Manufacturing performance by geography ($m), 2007-2008
    • Table 9.24: Piramal's snapshot
    • Table 9.25: Piramal Pharma Solutions' financial performance ($m), 2006-2007
    • Table 9.26: Piramal Pharma Solutions' business segments performance ($m), 2005-2007
    • Table 10.27: Jubilant's snapshot
    • Table 10.28: Jubilant's CRAMS financial performance ($m), 2003-2007
    • Table 10.29: Jubilant's CRAMS product segments performance ($m), 2006-2007
    • Table 10.30: Jubilant's performance by geography ($m), 2005-2007
    • Table 11.31: Aenova's snapshot
    • Table 12.32: Fareva's snapshot
    • Table 12.33: Fareva Pharmaceuticals' financial performance ($m), 2006-2008
    • Table 13.34: Nipro's snapshot
    • Table 13.35: Nipro's Pharmaceutical financial performance ($m), 2003-2007 *
    • Table 13.36: Siegfried's snapshot
    • Table 13.37: Siegfried's financial performance ($m), 2006-2007*
    • Table 13.38: Haupt's snapshot
    • Table 13.39: Divi's' snapshot
    • Table 13.40: Divi's financial performance ($m), 2003-2007
    • Table 13.41: Cambrex's snapshot
    • Table 13.42: Cambrex's financial performance ($m), 2005-2007*
    • Table 13.43: Recipharm's snapshot
    • Table 13.44: Recipharm's financial performance ($m), 2003-2008
    • Table 13.45: Archimica's snapshot
    • Table 13.46: Vetter's snapshot
    • Table 13.47: Famar's snapshot
    • Table 13.48: NextPharma's snapshot
    • Table 13.49: Other select contract manufacturers